Hepatic Care News
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Biopharma Stock News Bite - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Spikes on News Potential Treatment for Alcohol Use Disorder
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. The stock is trading at $2.0050, up $0.8750, gaining +77.0925% on volume of over 8o ...
-
Jill Nash: Women In Trucking Top Women to Watch in 2024
GFL is delighted to announce that our Vice-President, National Accounts and Brokers Jill Nash has been named one of Women In Trucking’s Top Women to Watch in Transportation in 2024. This accolade recognizes women who are top performers in the trucking and transportation industry, and who go the extra mile to support other women both within their own companies and industry wide. Awardees ...
-
Novel Drug Delivery System Unveiled: CD Formulation Launches Oral Thin Films Technology
In a groundbreaking development in the field of pharmaceuticals, CD Formulation, a prominent drug formulation company, has announced the launch of Oral Thin Film Technology. This cutting-edge drug delivery system is poised to revolutionize medication administration, offering patients a more convenient and effective treatment method. Oral Thin Film Technology is a user-friendly drug delivery ...
-
ATMP Sterility Testing
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
-
Amerigo Scientific Rolls Out Real-Time PCR Kits to Facilitate HAV Research
Amerigo Scientific, as a distributor focused on providing critical products and services to biomedical and life science communities, recently rolled out their cutting-edge real-time PCR kits for Hepatitis A virus (HAV) research. The new kits offer researchers excellent accuracy, sensitivity, and convenience in studying and analyzing HAV samples. Hepatitis A is a highly contagious viral ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Discover our top-selling Precellys kits!
For many years, scientists all around the globe have been using Precellys lysing and grinding kits, as they have been proven efficient and safe in a broad range of research areas including microbiology, pharmacology, cancer, forensic medicine, the environment, and even agronomy. Here below, discover our top three bestselling kits and find the perfect solution for your sample prep! ...
-
ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 in ...
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
Creative Diagnostics Expands Its Monoclonal Antibodies Offering to Customers
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. Monoclonal antibodies (mAbs) are generated by identical B cells that are cloned from a single parent cell. ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
LISCure`s Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
-
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
-
HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, today announced that Brain Wamhoff, Interim CEO, will present at the 34th Annual Piper Sandler Healthcare Conference being held November 29 – December 1 in New York City. The HemoShear management team will also participate in one-on-one meetings with investors. Meetings may be requested through Piper ...
-
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of 16.7% in the 45 mg ...
-
CD Formulation Launches GalNAc Coupling Modification Services for the Development of Drug Delivery Systems
Over the past decade, the CD Formulation’s expert team has made tireless efforts in the research and development of drug delivery systems, trying to improve the pharmacokinetics and pharmacodynamics of drugs. In order to achieve the optimal therapeutic effect, the required dose must be delivered at the target site at the appropriate time and rate. “We have developed various drug ...
-
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques ...
By MorphoSys AG
-
Bayer receives positive CHMP opinion for Eylea in the EU for treatment of preterm infants with retinopathy of prematurity
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
By Bayer AG
-
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results ...
By CohBar, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you